Derm Cases · Dermatology / Primary Care / Therapeutics
OSCE — prescribe a topical corticosteroid correctly: potency, site, FTU and safety
An 8-minute OSCE station on choosing topical corticosteroid potency by site and severity, fingertip-unit dosing, vehicle selection, weekly quantity limits, and avoiding face/flexure potency errors, tinea incognito and steroid withdrawal.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on choosing topical corticosteroid potency by site and severity, fingertip-unit dosing, vehicle selection, weekly quantity limits, and avoiding face/flexure potency errors, tinea incognito and steroid withdrawal.
Brief (to candidate)
A 26-year-old with flexural atopic eczema flare and a second lesion of thick palm plaque psoriasis asks for “strong steroid cream for the face and hands.” She previously used clobetasol on the eyelids for months. You have 8 minutes to choose appropriate potencies by site, teach fingertip units, set duration/review, and counsel on adverse effects and steroid phobia.
[8]Candidate instructions
- Match potency to site and disease thickness (face/flexures vs palms/soles).
- Name reference agents: hydrocortisone 1% (mild) and clobetasol 0.05% (very potent).
- Teach the fingertip unit (FTU) method with quantities.
- Set duration, step-down, and weekly dose limits.
- Warn about atrophy, periorificial dermatitis, tinea incognito, HPA suppression, and address TCS phobia.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Potency ladder | Mild (hydrocortisone 1%) → moderate → potent → very potent (clobetasol 0.05%); Indian four-tier or US Class I–VII frameworks acceptable if consistent[1][5] |
| Site matching | Face, eyelids, flexures, genitals: mild–moderate only, short courses; palms/soles/thick plaques: potent/very potent acceptable short-term with limits; avoid long-term potent facial TCS[1][2] |
| Vehicle | Ointment > cream for same molecule (occlusion); lotion/gel for hair-bearing; foam/solution for scalp as appropriate[1] |
| FTU dosing | 1 FTU ≈ 0.5 g ≈ 2 adult palms ≈ 2% BSA; give body-area FTU examples (face/neck ~2.5 FTU; one hand 1 FTU)[1][5] |
| Safety limits | Very potent adults: do not exceed roughly 50 g/week (lower in children); define stop/review date; step down rather than abrupt stop after prolonged use when relevant |
| Complications | Skin atrophy, striae, telangiectasia, periorificial dermatitis, glaucoma risk from periocular use, tinea incognito, rare HPA-axis suppression; pregnancy: prefer milder agents when possible[6] |
| Adherence counselling | Address steroid phobia with clear FTU teaching — under-use worsens disease as much as over-use harms skin[8] |
Model key actions
- Prescribe mild TCS for face/flexures and reserve clobetasol for thick non-facial plaques with time limits.[1][2]
- Demonstrate FTU-based quantity and set a review/step-down plan.[5]
- Warn about tinea incognito and chronic facial potent steroid misuse.[6]
Common errors
- Giving clobetasol for eyelids/face.
- Vague “apply sparingly” without FTU teaching.
- No duration or weekly quantity limit.
- Ignoring TCS phobia, leading to under-treatment of eczema.
- Missing tinea misdiagnosed as eczema and worsened by steroid.
References5ShowHide
- [1]Stacey SK, McEleney M. Topical Corticosteroids: Choice and Application. American Family Physician, 2021.PMID 33719380
- [2]Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. American Family Physician, 2020.PMID 32412211
- [5]Mehta AB, Nadkarni NJ, Patil SP, et al. Topical corticosteroids in dermatology. Indian Journal of Dermatology, Venereology and Leprology, 2016.PMID 27279294
- [6]Kokandi AA. Tinea Incognito. Clinical, Cosmetic and Investigational Dermatology, 2024.PMID 38737948
- [8]Li AW, Yin JW, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatology, 2017.PMID 28724128